

ORIGINAL RESEARCH

The golden 35 min of stroke intervention with ADAPT: effect of thrombectomy procedural time in acute ischemic stroke on outcome

Ali Alawieh,¹ Alyssa K Pierce,² Jan Vargas,² Aquilla S Turk,² Raymond D Turner,² M Imran Chaudry,² Alejandro M Spiotta²

¹Medical Scientist Training Program, Medical University of South Carolina, Charleston, South Carolina, USA

²Department of Neurosurgery, Medical University of South Carolina, Charleston, South Carolina, USA

Correspondence to

Dr Alejandro M Spiotta, Department of Neurosciences, Division of Neurosurgery, Medical University of South Carolina, 96 Jonathan Lucas Street, CSB 210, Charleston, SC 29425, USA; spiotta@musc.edu

Received 16 February 2017
Revised 24 March 2017
Accepted 25 March 2017
Published Online First
2 May 2017

ABSTRACT

Introduction In acute ischemic stroke (AIS), extending mechanical thrombectomy procedural times beyond 60 min has previously been associated with an increased complication rate and poorer outcomes.

Objective After improvements in thrombectomy methods, to reassess whether this relationship holds true with a more contemporary thrombectomy approach: a direct aspiration first pass technique (ADAPT).

Methods We retrospectively studied a database of patients with AIS who underwent ADAPT thrombectomy for large vessel occlusions. Patients were dichotomized into two groups: 'early recan', in which recanalization (recan) was achieved in ≤ 35 min, and 'late recan', in which procedures extended beyond 35 min.

Results 197 patients (47.7% women, mean age 66.3 years) were identified. We determined that after 35 min, a poor outcome was more likely than a good (modified Rankin Scale (mRS) score 0–2) outcome. The baseline National Institutes of Health Stroke Scale (NIHSS) score was similar between 'early recan' (n=122) (14.7 \pm 6.9) and 'late recan' patients (n=75) (15.9 \pm 7.2). Among 'early recan' patients, recanalization was achieved in 17.8 \pm 8.8 min compared with 70 \pm 39.8 min in 'late recan' patients. The likelihood of achieving a good outcome was higher in the 'early recan' group (65.2%) than in the 'late recan' group (38.2%; $p < 0.001$). Patients in the 'late recan' group had a higher likelihood of postprocedural hemorrhage, specifically parenchymal hematoma type 2, than those in the 'early recan' group. Logistic regression analysis showed that baseline NIHSS, recanalization time, and atrial fibrillation had a significant impact on 90-day outcomes.

Conclusions Our findings suggest that extending ADAPT thrombectomy procedure times beyond 35 min increases the likelihood of complications such as intracerebral hemorrhage while reducing the likelihood of a good outcome.

INTRODUCTION

Current interventions to restore blood flow after acute ischemic stroke (AIS) include administration of systemic IV tissue plasminogen activator (IV tPA), IA thrombolysis, and mechanical thrombectomy.^{1–5} Randomized controlled trials on endovascular interventions, including balloon angioplasty, IA thrombolysis, stenting, aspiration, and mechanical maceration, have shown that these interventions can reduce the severity of AIS with an

extended treatment window beyond 8 hours of onset.^{3–21}

Despite the type of acute treatment, studies on AIS have focused on the time from symptom onset to treatment when evaluating outcomes. We have previously determined that, in the case of mechanical thrombectomy, procedural time, rather than time from onset to treatment, may have a stronger impact on outcomes in these patients. In particular, procedures that extended beyond 60 min from groin puncture to recanalization resulted in increased incidence of complications, increased cost, and worse outcomes.²² Mechanical thrombectomy in this study was performed using Penumbra separators and, less frequently, stent retrievers.²² Following this study, the introduction of a direct aspiration at first pass technique (ADAPT) with large bore aspiration catheter has significantly reduced the time required to achieve satisfactory angiographic outcomes.^{23 24} ADAPT has been shown to be a fast and effective method for achieving thrombectomies with good clinical and angiographic outcomes while reducing procedure time to around 30 min, on average.^{23 24} The purpose of this study is to re-evaluate, using ADAPT, if a similar relationship between procedural time and outcome still holds true, and whether further reduction in procedure time to within the first half hour results in better outcomes.

METHODS

Patient selection

We retrospectively studied a database of patients with AIS involving the anterior circulation who underwent ADAPT thrombectomy at a tertiary care center between December 2012 and July 2015. Candidacy for intervention was determined by CT perfusion imaging, irrespective of time of onset.²⁵ The study was approved by the institutional review board. Every patient underwent postprocedural CT within 12–24 hours routinely and the presence of hemorrhage on CT was determined by a blinded neuroradiologist. In cases where there was question of contrast staining versus petechial hemorrhage, subsequent CT scans were reviewed to assess for washout of contrast. If the follow-up imaging did not clarify contrast staining versus petechial hemorrhage, petechial hemorrhage was assumed. None of the patients required a decompressive craniotomy. ADAPT has been described previously.^{23 24} For device selection, the largest caliber aspiration



To cite: Alawieh A, Pierce AK, Vargas J, et al. *J NeuroIntervent Surg* 2018;**10**:213–220.

catheter that the vessel can accommodate is selected. For M1 thrombi, the 5 MAX, 5 MAX ACE, 064 and 068 catheters were primarily employed. In smaller caliber or more distal vessels, the technique is employed with either a 4 Max or 3 Max reperfusion catheter (Penumbra, Alameda, California, USA). A maximum of two to three attempts are performed with ADAPT before the use of additional devices such as stent retrievers at the discretion of the operator. All patients received conscious sedation during the procedure, and a permissive hypertensive blood pressure was maintained during procedures to allow collaterals, followed by blood pressure control according to standard institutional protocols.

Data collection

Patient data were collected by reviewing patient charts, procedural records, and angiograms, and included preprocedural, procedural, and outcome variables. Preprocedural variables were age, gender, initial National Institutes of Health Stroke Scale (NIHSS) score, comorbidities, time of symptom onset, whether IV tPA was given and whether only proximal vessels were involved. Procedural variables included recanalization status of the affected vessel, as determined by the Thrombolysis in Cerebral Infarction (TICI) scale, intraprocedural complications, time to recanalization, the total number of passes, the number of passes with ADAPT only, and the presence of hemorrhage on a postprocedural head CT scan. Hemorrhage was classified using the European Cooperative Acute Stroke Study radiological classification for hemorrhagic infarcts (HI1 and HI2), parenchymal hematomas (PH1 and PH2), and subarachnoid hemorrhage.²⁶

For parts of the statistical analysis, time to recanalization was studied as a continuous variable. Time to recanalization was determined from percutaneous groin access (time zero) to the time that the affected vessel was recanalized. Time was monitored in minutes and seconds based on review of the time stamp of the angiographic images. If the patient had an intraprocedural complication requiring abortion of the procedure (eg, vessel rupture), recanalization time was defined as time of groin puncture to the time when the complication was documented. Patients were dichotomized into two groups: 'early recan', in which recanalization was achieved in ≤ 35 min, and 'late recan', in which procedures extended beyond 35 min. A duration of 35 min was chosen as a cut-off point since the curves representing the percentage of patients with good and poor outcomes intersect at around 35 min, denoting the procedure time above which a poor outcome becomes more likely. A good outcome was defined as a modified Rankin Scale (mRS) score 0–2 and a poor outcome as an mRS score 3–6.

Outcomes

Functional outcome was assessed by 90-day follow-up mRS score, 90-day NIHSS score, and length of stay.

Statistical analysis

Statistical analyses were performed using SAS V9.4 (SAS Institute, Cary, North Carolina, USA), Graphpad Prism 6 (Graphpad, La Jolla, California, USA). A population of 197 subjects was analyzed using descriptive statistics to characterize demographics and other clinical variables describing treatment, complications, and outcomes. Differences between the recanalization time groups ('early recan' and 'late recan') based on these variables were tested using Student's *t* test for continuous measures and a χ^2 test for categorical measures. Differences between the device groups were tested using Fisher's exact test for categorical measures with expected cell sizes < 5 . All tests were

two-sided and assessed at a significance level of 0.05. Multivariate logistic regression was used to predict the outcome mRS score at 90 days of 0–2 based on several prespecified prognostic variables, including time to recanalization. Model performance was assessed using the Hosmer–Lemeshow test and *c* statistic.

A logistic regression analysis was performed to determine if the probability of a good outcome at 90 days was affected by prespecified prognostic variables. One hundred and forty-eight subjects were included in the model, of whom 84 subjects (57%) had a good outcome. Seventeen subjects with a missing outcome and 32 subjects with missing values for a prognostic variable (onset to groin) were excluded from the model. The variables included in the multivariate model were recanalization time (as a categorical variable of 'early recan' (≤ 35 min), baseline NIHSS score, revascularization (post-TICI flow of 2b or 3), presence of hemorrhage or procedural complications, time from symptom onset to CT in hours, time from CT to procedure start in hours, treatment with IA or IV tPA, age, and indicators of atrial fibrillation, diabetes, hypertension, and number of passes.

For analyses shown in figure 2, a third-degree polynomial best-fit curve was determined using Graphpad prism based on the highest correlation coefficient (R^2) and compared with other models of fitting. Runs test was used to assess for significant deviation from actual data. A Kruskal–Wallis test with Dunn's multiple comparisons test was used to compare the difference in the number of vessels involved at different procedure durations (figure 2B), and the best fit for linear regression was used to determine the correlation between the incidence of PH2-type hemorrhage and procedure time.

RESULTS

Patient baseline characteristics

A total of 197 patients (mean age 66.3 ± 14 , 45.7% female) underwent ADAPT thrombectomy for AIS during the study period. The average NIHSS at presentation was 15.2 ± 7 , and average time from symptom onset to groin puncture was 7.9 ± 6.1 hours (table 1). The mean NIHSS score was similar




Figure 1 Distribution of 90-day modified Rankin Scale (mRS) outcome. Patients in the 'late recan' group (recanalization time > 35 min) were more likely to have poor outcomes (mRS > 2), and had a higher percentage of patients who had either died or were in a persistent vegetative state compared with 'early recan' group (recanalization time ≤ 35).

between 'early recan' (14.7 ± 6.9) and 'late recan' (15.9 ± 7.2 , $p=0.207$) groups. The two groups also had similar rates of comorbidities, including atrial fibrillation, diabetes and hypertension, rate of preprocedural IV tPA administration, rate of only proximal vessel involvement, and average time from symptom onset to groin puncture ($p>0.05$). Patients in the 'early recan' group were more likely to be younger than those in the 'late recan' group (64.2 ± 14.1 vs 69.9 ± 13.3 , $p=0.005$).

Recanalization

Mean time for recanalization was 36.9 ± 34.2 min among all patients, and was significantly longer in the 'late recan' group

(68.4 ± 38.4 min vs 18.4 ± 8.4 min, $p<0.001$). Final TICI flow $\geq 2b$ was achieved in 96.4% of patients ($n=190$), TICI 3 was achieved in 59.4% of patients ($n=117$), 2c in 8.1% ($n=16$) and 2b in 28.9% ($n=57$). Patients in the 'early recan' group were more likely to achieve a TICI $\geq 2b$ (99.2% vs 92.0%, $p=0.013$).

Devices used in the ADAPT procedure are primarily the largest caliber aspiration catheter that the vessel can accommodate, including 3 MAX, 4 MAX, 5 MAX, 5 MAX ACE, 064 and 068 catheters. Upon failure of ADAPT, additional devices, including stent retrievers and carotid stents, are used. No balloon-guide catheters were used in these procedures.




Figure 2 Outcomes at 90 days by recanalization time group. (A) The distribution of patients by good and poor outcomes and the number of patients at different recanalization time groups. Solid lines connect the actual data points for the distribution of percentage of good outcomes (blue) and bad outcomes (red). Dotted lines show the best fit curve for the distribution of percentage of good outcomes (blue) and bad outcomes (red). The arrow shows the point of intersection of curves with the 50% line denoting equal probability of good and bad outcomes. Best-fit curves are third-order polynomials with $R^2=0.54$. Deviation from the curves was not significant (runs test; $p=0.41$). (B) Comparison of the number of vessels occluded in the 55–75 min recanalization time group with the 0–35 min and 35–55 min groups, showing significantly higher number of vessels occluded in the 55–75 min group than in the other two groups. There was no significant difference in the number of vessels occluded in the 0–35 min and 35–55 min groups. A Kruskal–Wallis test was used with Dunn's multiple comparisons; * $p<0.05$; ** $p<0.01$. (C) Correlation between percentage incidence of parenchymal hematoma (PH)2-type hemorrhage and recanalization time showing a significant positive correlation (Pearson's correlation, $R^2=0.447$, $p=0.03$), indicating a higher incidence of PH2-type hemorrhage with increased recanalization time. The incidence of PH2-type hemorrhage with recanalization time beyond 35 min was higher than the average of this study (6.6%) and higher than that found in previous randomized controlled trials (RCTs) using different interventions (4.3%).^{4 18–21}

Table 1 Patient characteristics

Variable	No of patients	Total	'Early recan' ≤35 min	'Late recan' >35 min	p Value
Preprocedure					
Age (years)	197	66.3 (14)	64.2 (14.1)	69.9 (13.3)	0.005
Female, n (%)	197	90 (45.7)	55 (45.1)	35 (46.7)	0.828
White, n (%)	197	112 (56.9)	67 (54.9)	45 (60)	0.484
Baseline NIHSS	197	15.2 (7)	14.7 (6.9)	15.9 (7.2)	0.207
Time from onset to groin (h)	162	7.9 (6.1)	8.35 (6.54)	7.03 (5.05)	0.19
IV tPA, n (%)	197	70 (35.5)	46 (37.7)	24 (32)	0.417
Proximal occlusion	197	141 (71.6)	85 (69.7)	56 (74.7)	0.450
Comorbidities, n (%)					
AF	188	42 (22.3)	29 (24.8)	13 (18.3)	0.301
Diabetes	188	39 (20.7)	25 (21.4)	14 (19.7)	0.787
Hypertension	188	124 (66.0)	71 (60.7)	53 (74.6)	0.051
Procedure					
Time to recanalization (min)	197	37.7 (35.9)	17.8 (8.8)	70 (39.8)	<0.001
Final TIC1 flow, n (%)	197				<0.001
0		1 (0.5)	1 (0.8)	0 (0.0)	
1		3 (1.5)	0 (0.00)	3 (4)	
2a		3 (1.5)	0 (0.00)	3 (4)	
2b		57 (28.9)	26 (21.3)	31 (41.3)	
2c		16 (8.1)	12 (9.8)	4 (5.3)	
3		117 (59.4)	83 (68)	34 (45.3)	
Final TIC1 flow, n (%)	197				0.013
0–2a		7 (3.6)	1 (0.8)	6 (8.0)	
2b–3		190 (96.4)	121 (99.2)	69 (92.0)	
Complications, n (%)	197	2 (1.0)	1 (0.8)	1 (1.3)	0.999
Hemorrhage, all types (n (%))	197	62 (31.5)	29 (23.8)	33 (44.0)	0.003
Hemorrhage, PH2	197	13 (6.6)	3 (2.5)	10 (13.3)	0.006
Hemorrhage, others	197	49 (24.9)	26 (21.3)	23 (30.7)	0.140
Device, n (%)					
Stent retrievers*	197	46 (23.4)	16 (13.1)	30 (40.0)	<0.001
Carotid stenting	197	10 (5.1)	2 (1.6)	8 (11.3)	0.007
Other	197	143 (72.6)	105 (86.1)	38 (50.7)	<0.001
Number of passes					
1	197	75 (38.1)	60 (49.2)	15 (20.0)	<0.001
2		80 (40.6)	46 (37.7)	34 (45.3)	
3		35 (17.8)	16 (13.1)	19 (25.3)	
4		7 (3.6)	0 (0.0)	7 (9.3)	
Number of ADAPT passes					
1	197	100 (50.8)	68 (55.7)	32 (42.7)	0.115
2		81 (41.1)	47 (38.5)	34 (45.3)	
3		16 (8.1)	7 (5.7)	9 (12.0)	
Outcome (90 day)					
mRS dichotomized, n (%)	180				<0.001
mRS 0–2		99 (55)	73 (65.2)	26 (38.2)	
mRS >2		81 (45)	39 (34.8)	42 (61.8)	
Death, n (%)	197	29 (14.7)	13 (10.7)	16 (21.3)	0.040
NIHSS (90 days)	98	2.3 (3.4)	1.7 (2.9)	3.3 (4.1)	0.034
Length of stay (days)	188	8.7 (17.1)	8.2 (12.9)	9.5 (22.5)	0.612

Values are n (%) or mean (SD).

χ² test (Fisher's exact test for small cell sizes) or Student's t test for the entire patient cohort.

*Stent retrievers include Solitaire and Trevo.

Additionally, we dichotomized the cohort into patients in whom recanalization times were achieved in ≤35 min 'early recan') and those in whom recanalization times extended beyond 35 min ('late recan').

ADAPT, a direct aspiration first pass technique; AF, atrial fibrillation; IV tPA, IV tissue plasminogen activator; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; PH2, parenchymal hematoma type 2; TIC1, Thrombolysis in Cerebral Infarction.

Patients in the 'late recan' group were more likely to require additional devices such as stent retrievers and carotid stents (table 1). In addition, patients in the 'late recan' group required a significantly higher number of total passes than the

'early recan' group (p<0.001); however, the number of ADAPT passes was not significantly different between the two groups (p=0.115). The maximum number of ADAPT passes was 3.

Table 2 Results of the univariate and multivariable logistic regression for predictors of good outcome

Variable	Univariate (n=148)			Multivariate (n=148)			
	OR	95% CI	p Value	Included in model?	OR	95% CI	p Value
Age	0.97	0.94 to 0.99	0.003	Yes	0.99	0.96 to 1.01	0.331
Female	0.62	0.32 to 1.19	0.148	Yes*	1.44	0.64 to 3.25	0.380
White	1.01	0.52 to 1.95	0.985	Yes*	1.03	0.46 to 2.27	0.949
Baseline NIHSS	0.88	0.84 to 0.93	<0.001	Yes	0.89	0.82 to 0.94	<0.001
Time from onset to groin	0.99	0.99 to 0.99	0.039	Yes	0.99	0.99 to 0.999	0.061
IV tPA	1.10	0.56 to 2.15	0.788	No			
Groin time	1.02	0.97 to 1.06	0.47	No			
Early recanalization (≤ 35 min)	2.82	1.41 to 5.62	0.003	Yes	0.35	0.15 to 0.83	0.017
Device: stent retrievers	0.77	0.35 to 1.70	0.546	No			
Device: Precise	1.29	0.30 to 5.60	0.999	No			
Device: other	1.24	0.58 to 2.63	0.718	No			
Number of passes=1	1.18	0.52 to 2.367	0.401	No			
Number of passes=2	1.27	0.56 to 2.84	0.572	No			
Number of passes >2	0.54	0.27 to 1.07	0.08	No			
Post-TICI flow 'good' (2b–3)	2.73	0.485 to 15.41	0.237	Yes*	0.39	0.05 to 3.22	0.384
AF	2.04	0.86 to 4.81	0.101	Yes*	0.24	0.07 to 0.77	0.017
Diabetes	1.00	0.44 to 2.24	0.991	Yes*	1.11	0.38 to 3.20	0.850
Hypertension	0.83	0.42 to 1.61	0.574	Yes*	1.63	0.67 to 3.97	0.280
Waking Up	2.82	0.57 to 14.1	0.189	No			
Complications	0.37	0.03 to 4.21	0.408	No			
Hemorrhage	0.38	0.19 to 0.76	0.01	Yes	1.75	0.71 to 4.31	0.227
Hemorrhage: PH2 subtype	0.47	0.13 to 1.8	0.327	Yes*	1.41	0.25 to 7.90	0.697

Variables achieving statistical significance are highlighted in bold type.

*Although not statistically significant variable on univariate analysis, it was included owing to clinical significance.

AF, atrial fibrillation; IV tPA, IV tissue plasminogen activator; NIHSS, National Institutes of Health Stroke Scale; PH2, parenchymal hematoma type 2; TICI, Thrombolysis in Cerebral Infarction.

Procedural complications

Only two (1%) patients developed intraprocedural complications other than hemorrhage—one patient from each group. One patient developed ST-segment depression with elevated troponin levels, and another patient developed non-flow limiting internal carotid artery dissection that was treated with stent placement.

Among all the patients, 31.5% (n=62) developed hemorrhage of any subtype identified on a postprocedural CT scan (table 1). Patients in the 'late recan' group were more likely to develop hemorrhage (4.0% vs 23.8%, p=0.003). The 'late recan' group had a higher likelihood of developing a PH2-type hemorrhage, but not other subtypes (table 1).

Incidence of PH2-type hemorrhage

The incidence of PH2 demonstrated a significant positive correlation with recanalization time; higher recanalization time correlated with higher incidence of PH2 (figure 2C). The incidence of PH2 was higher in the 'late recan' group than the mean PH2 of this study. Additionally, the mean PH2 rate in this sample was higher than the pooled mean from previous randomized controlled trials on endovascular stroke therapy.^{4 18–21}

Neurological outcome

Ninety-day mRS was used to determine the neurological outcome of patients, and these data were available for 180 patients (91.4%) at the time of data interpretation. The overall rate of good outcome defined as an mRS score of 0–2 at 90 days was 55% (n=99) among all patients (table 1), and was higher in the 'early recan' group (65.2% vs 38.2%, p<0.001). In addition, patients in the 'late recan' group had a higher

likelihood of death or being in a persistent vegetative state (mRS 5–6) (30.9% vs 15.2%, p=0.012) (figure 1).

The NIHSS at 90 days was available for 50% of the patients (n=98) with a mean score of 2.3±3.4. Patients in the 'early recan' group were more likely to have a lower NIHSS at 90 days (table 1). There was no difference in length of stay after the procedure between groups.

Factors affecting outcome

Baseline NIHSS, early recanalization, and atrial fibrillation were found to have a significant impact on neurological outcome measured by mRS at 90 days. A higher NIHSS score at baseline was associated with a decreased likelihood of an mRS ≤ 2 at 90 days (OR=0.89). The presence of atrial fibrillation was also associated with decreased likelihood of a good outcome with an OR of 0.24 (table 2). Achievement of recanalization within 35 min ('early recan') was also associated with a significant increase in the likelihood of a good outcome at 90 days with OR=2.82. As the time to achieve recanalization increased beyond 35 min, the percentage of patients with poor outcome at 90 days became higher than the percentage of patients with good outcomes up to 65 min (figure 2A).

Among patients with recanalization time >35 min, a subset of patients with recanalization time between 55 and 75 min had a nearly equal likelihood of good and poor outcomes resulting in a transient shift in the distribution curve (figure 2A). Further analysis of the characteristics of this specific subgroup showed that a significantly higher number of vessels were involved (carotid bifurcation, M1, M2, A1 ... etc) than in the 0–35 min group (more likely single vessel, ie, M1 occlusion) (figure 2B). In contrast, patients within the 35–55 min group showed a

Table 3 Factors associated with outcome grouped by recanalization time

Variable	N	Total	Good outcome mRS 0–2	Poor outcome mRS 3–6	p Value
<i>Early recan</i>					
Age	110	63.56 (14.51)	61.92 (14.67)	66.94 (13.75)	0.09
Female	110	52 (47.3)	32 (43.2)	20 (55.6)	0.225
White	110	62 (56.4)	41 (55.4)	21 (58.3)	0.771
Baseline NIHSS	110	14.362 (6.94)	12.49 (5.07)	19.00 (8.17)	<0.001
Onset to groin (hours)	110	8.35 (6.57)	7.52 (6.22)	9.96 (7.01)	0.103
IV tPA	110	40 (36.4)	26 (35.1)	14 (38.9)	0.701
AF	110	22 (20.0)	15 (20.3)	7 (19.4)	0.919
Diabetes	110	22 (20.0)	18 (24.3)	4 (11.1)	0.104
Hypertension	110	74 (67.3)	49 (66.2)	25 (69.4)	0.735
Recanalization time (min)	110	18.55 (8.37)	17.93 (7.67)	19.81 (9.66)	0.313
Final TICl flow	110				0.707
0		1 (0.9)	1 (1.4)	0 (0.0)	
1		0 (0.0)	0 (0.0)	0 (0.0)	
2a		0 (0.0)	0 (0.0)	0 (0.0)	
2b		22 (20.0)	14 (18.9)	8 (22.2)	
2c		10 (9.1)	8 (10.8)	2 (5.6)	
3		77 (70.0)	51 (68.9)	26 (72.2)	
Final TICl flow	110				0.484
0–2a		1 (0.9)	1 (1.35)	0 (0.0)	
2b–3		109 (99.1)	73 (98.6)	36 (100.0)	
Complication	110	2 (1.8)	0 (0.0)	2 (5.6)	0.105
Hemorrhage	110	25 (22.7)	12 (16.2)	13 (36.1)	0.019
Device: Trevo	110	5 (4.5)	3 (4.1)	2 (5.6)	0.662
Device: Solitaire	110	9 (8.2)	7 (9.5)	2 (5.6)	0.715
Device: Precise	110	1 (0.9)	1 (1.4)	0 (0.0)	1.00
Device: other	110	95 (86.4)	63 (85.1)	32 (88.9)	0.59
<i>Delayed recan</i>					
Age	70	70.01 (13.22)	65.96 (12.84)	72.41 (12.99)	0.048
Female	70	35 (50.0)	10 (38.5)	25 (56.8)	0.138
White	70	43 (61.4)	16 (61.5)	27 (61.4)	0.988
Baseline NIHSS	70	15.96 (7.42)	13.12 (7.38)	17.36 (6.99)	0.013
Onset to groin (hours)	70	7.03 (5.17)	6.03 (4.47)	7.72 (5.56)	0.241
IV tPA	70	22 (31.4)	11 (42.3)	11 (25.0)	0.132
AF	70	13 (18.6)	3 (11.5)	10 (22.7)	0.345
Diabetes	70	13 (18.6)	5 (19.2)	8 (18.2)	0.913
Hypertension	70	32 (45.7)	8 (30.8)	24 (54.5)	0.054
Recanalization time (min)	70	68.51 (38.91)	62.81 (25.30)	71.89 (45.01)	0.349
Final TICl flow	70				0.299
0		0 (0.0)	0 (0.0)	0 (0.0)	
1		3 (4.3)	0 (0.0)	3 (6.8)	
2a		3 (4.3)	1 (3.8)	2 (4.5)	
2b		29 (41.4)	8 (30.8)	21 (47.7)	
2c		4 (5.7)	2 (7.7)	2 (4.5)	
3		31 (44.3)	15 (57.7)	16 (36.4)	
Final TICl flow	70				0.269
0–2a		6 (8.6)	1 (3.8)	5 (11.4)	
2b–3		64 (91.4)	25 (96.2)	39 (88.6)	
Complication	70	1 (1.4)	1 (3.8)	0 (0.0)	0.371
Hemorrhage	70	29 (41.4)	10 (38.5)	19 (43.2)	0.698
Device: Trevo	70	13 (18.6)	4 (15.4)	9 (20.5)	0.424
Device: Solitaire	70	18 (25.7)	8 (30.8)	10 (22.7)	0.457
Device: Precise	70	8 (11.4)	4 (15.4)	4 (0.1)	0.458
Device: other	70	36 (51.4)	14 (53.8)	22 (50.0)	0.756

Values are n (%) or mean (SD).

χ² Test (Fisher’s exact test for small cell sizes) or Student’s t test for the entire patient cohort.

AF, atrial fibrillation; IV tPA, IV tissue plasminogen activator; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; TICl, Thrombolysis in Cerebral Infarction.

lower likelihood of good outcome even with a comparable number of vessels involved in the procedure (figure 2B).

Characteristics of early and late recanalization groups

When the groups were analyzed independently based on outcome, patients with good outcome were more likely to have a lower NIHSS score at presentation than those with a poor outcome (table 3). Age was similar among patients with good and poor outcomes in the ‘early recan’ group, but in the ‘late recan’ group, patients with poor outcome were likely to be older than those with good outcome. Overall hemorrhage was more likely to be associated with a poor outcome in the ‘early recan’ subset of patients, but not the ‘late recan’ group (table 3).

DISCUSSION

In recent years, mechanical thrombectomy has been shown to significantly reduce the severity of disability after AIS with an extended treatment window.^{17–20} In a previous study employing older-generation thrombectomy techniques (Penumbra separator and stent retriever),²² we have shown that the duration of mechanical thrombectomy procedures is an important predictor of patient outcomes. Faster procedure time was associated with improved patient outcomes, and thrombectomies extending beyond 60 min increased complications and cost while diminishing the likelihood of a good outcome.²² Since that publication, new devices and techniques have been developed to improve the speed and quality of thrombectomies, such as the direct aspiration at first pass technique, or ADAPT.^{23 24} With ADAPT, time to recanalization can be further reduced to, on average, 30–40 min.^{22 23}

We investigated whether the relation between procedure time and outcome still exists with ADAPT. The duration of the mechanical thrombectomy procedure has been shown to be a predictor of outcome, independent of time from symptom onset to treatment, the most commonly studied and best described predictor. To evaluate the effect of procedure time in this study, patient eligibility was determined by CT perfusion imaging that defines the ischemic penumbra, and not by the time from symptom onset. In this study, we demonstrated that patients with a procedure time of ≤ 35 min are more likely to have a better outcome at 90 days than patients with a longer procedure time. In addition, ‘late recan’ was associated with decreased likelihood of achieving a good TICI flow ($\geq 2b$), increased likelihood of hemorrhage, specifically PH2, at postprocedural CT imaging, and increased use of devices, which can drive up the cost of procedure.²² Patients in the ‘late recan’ group had a higher incidence of PH2-type hemorrhage. We also showed a significant positive correlation between procedure time and the incidence of PH2, a serious complication of neuroendovascular procedures. The mean PH2 incidence in this study population was higher than that observed in major clinical trials in neuroendovascular therapy of AIS^{4 18–21} (6.6% vs 4.3%). This finding is probably explained by the less stringent inclusion criteria in this study population compared with the randomized controlled trials. Patients of more advanced age, lower Alberta Stroke Program Early CT Score, and multiple intracranial occlusions as well as tandem occlusions with carotid bifurcation stenosis were included in this study sample.

Patients in the ‘late recan’ group required over twice as much time to achieve thrombectomy. The rationale behind using 35 min as the cut-off point in dichotomizing patients was that the ratio of good-to-poor outcome at increasing recanalization times is 1 at approximately 35 min, which reflects an equal percentage of good and bad outcomes (50%) at 35 min procedure

time. After 35 min, the percentage of patients with good outcomes decreases and less favorable outcomes increase. This cut-off point was determined by constructing the best-fit curve of the distribution of percentage of patients with good outcomes at different recanalization times, and then identifying the point at which this curve intersects the curve representing bad outcomes (figure 2A). It is important to note that 35 min does not represent an optimal procedure time, but rather represents the duration beyond which a bad outcome is more likely than a good one.

Among patients with recanalization time >35 min, a subset of patients with recanalization time between 55 and 75 min had a nearly equal likelihood of good and poor outcomes, resulting in a second inflection point in the distribution curve; however, this point is not conserved in the best-fit curves, and the higher ratio of good-to-bad outcome is not sustained beyond this one data point (figure 2A). Further analysis of the characteristics of this specific subgroup to ascertain any differences in those patients whose procedures extended to around 60 min, showed that a significantly higher number of vessels were involved in the procedure compared with the 0–35 min group, explaining the delay in achievement of recanalization. These patients probably represent a subset of patients with very robust collaterals with more vascular reserve that prevented penumbra progression to infarction. In contrast patients within the 35–55 min group showed a lower likelihood of good outcome than the 0–35 min group, even with a comparable number of vessels involved in the procedure.

Patients with a procedure time longer than 35 min had a twofold higher likelihood of dying or being in a persistent vegetative state. While accounting for other major clinical variables that might affect neurological outcomes, longer time to recanalization was independently associated with a decreased likelihood of a good outcome at 90 days after treatment. These findings support previous studies on the influence of procedure time on outcome after thrombectomy^{22 27} and demonstrate that the same findings are consistent using ADAPT, with one notable exception—the primary inflection point occurs approximately 25 min earlier than with older-generation thrombectomy strategies (stent retriever and Penumbra separator).² Thus the ‘golden hour’ of thrombectomy procedures is now described as the ‘golden half-hour’.

Findings of this study may have implications for determination of the endpoints of mechanical thrombectomy. Although successful recanalization is associated with improved outcomes of patients, the use of multiple attempts, and thus longer procedure time, to achieve favorable angiographic outcomes is likely to be counterproductive while increasing costs.²⁸ However, although several trials have demonstrated a negative relationship between procedure time and neurological outcome after thrombectomy, the natural history of large vessel occlusion remains so poor that including procedure time as a potential endpoint remains at the judgement of the operator.

Limitations

Patients in the ‘late recan’ group were older, which might have contributed to the variation in functional outcomes across the groups. However, baseline NIHSS, procedure time, and a history of atrial fibrillation, were found to be predictors of outcome on multivariate analysis, whereas age was not. A lower baseline NIHSS score was a significant predictor of good outcomes in the ‘early recan’ group, but not in the ‘late recan’ group. This is probably a surrogate for patients with poor collaterals, and underscores the importance of early recanalization in patients with a

low NIHSS score. Although the pathophysiological processes underlying the relationship between procedure time and outcome is not fully elucidated, the likely hypothesis is that longer procedure times are associated with increased stress on collateral circulation in the penumbra, resulting in a secondary ischemic insult that accelerates the loss of salvageable penumbra.

This study is the first to evaluate the relationship between the duration of ADAPT procedure and neurological outcomes in patients with AIS. A large number of patients were enrolled from a single institution in this study, which minimizes procedural variability and disparities in perioperative patient care. Angiographic outcomes were blindly adjudicated and neurological outcomes were assessed by a stroke neurologist not involved in data collection.

CONCLUSION

Mechanical thrombectomy is increasingly used in AIS therapy and fast, safe and effective approaches such as ADAPT are continuously evolving. Our findings suggest that extending ADAPT thrombectomy procedure times beyond 35 min increases the risk of hemorrhage and device cost rates while worsening outcomes. These data suggest that after a time window of 35 min during the ADAPT procedure, it might be relevant to reassess the risks and benefits of reattempting failed thrombectomy cases.

Contributors Each author listed above should receive authorship credit based on the material contribution to this article, their revision of this article, and their final approval of this article for submission to this journal.

Competing interests Disclosures: AMS: Penumbra consulting, honorarium, speaker bureau; Pulsar Vascular consulting, honorarium, speaker bureau; Microvention consulting, honorarium, speaker bureau, research; Stryker consulting, honorarium, speaker bureau. AST, RDT, and MIC: Codman consulting, honorarium, speaker bureau, research funding; Covidien consulting, honorarium, speaker bureau; Penumbra consulting, honorarium, speaker bureau, research grants; Microvention consulting, honorarium, speaker bureau, research grants; Blockade—stock, consulting, honorarium, speaker bureau; Pulsar vascular stock, consulting, honorarium, speaker bureau, research; Medtronic consulting, honorarium, speaker bureau.

Ethics approval Medical University of South Carolina institutional review board.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- Mozaffarian D, Benjamin EJ, Go AS, *et al.* Executive summary: heart disease and stroke statistics—2016 update: a report from the American Heart Association. *Circulation* 2016;133:447–54.
- Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. *N Engl J Med* 1995;333:1581–7.
- Nogueira RG, Lutsep HL, Gupta R, *et al.* Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. *Lancet* 2012;380:1231–40.
- Saver JL, Jahan R, Levy EI, *et al.* Solitaire flow restoration device versus the Merci retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. *Lancet* 2012;380:1241–9.
- Nam J, Jing H, O'Reilly D. Intra-arterial thrombolysis vs. standard treatment or intravenous thrombolysis in adults with acute ischemic stroke: a systematic review and meta-analysis. *Int J Stroke* 2015;10:13–22.
- Adams HP Jr, Adams RJ, Brott T, *et al.* Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. *Stroke* 2003;34:1056–83.
- Furlan A, Higashida R, Wechsler L, *et al.* Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. *Prolyse in Acute Cerebral Thromboembolism. JAMA* 1999;282:2003–11.
- Gralla J, Brekenfeld C, Mordasini P, *et al.* Mechanical thrombolysis and stenting in acute ischemic stroke. *Stroke* 2012;43:280–5.
- Levy EI, Ecker RD, Horowitz MB, *et al.* Stent-assisted intracranial recanalization for acute stroke: early results. *Neurosurgery* 2006;58:458–63; discussion -63.
- Lin R, Vora N, Zaidi S, *et al.* Mechanical approaches combined with intra-arterial pharmacological therapy are associated with higher recanalization rates than either intervention alone in revascularization of acute carotid terminus occlusion. *Stroke* 2009;40:2092–7.
- Lisboa RC, Jovanovic BD, Alberts MJ. Analysis of the safety and efficacy of intra-arterial thrombolytic therapy in ischemic stroke. *Stroke* 2002;33:2866–71.
- Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. *Stroke* 2007;38:967–73.
- Ringer AJ, Qureshi AI, Fessler RD, *et al.* Angioplasty of intracranial occlusion resistant to thrombolysis in acute ischemic stroke. *Neurosurgery* 2001;48:1282–8; discussion 1288–90.
- Smith WS, Sung G, Saver J, *et al.* Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. *Stroke* 2008;39:1205–12.
- Tenser MS, Amar AP, Mack WJ. Mechanical thrombectomy for acute ischemic stroke using the MERCI retriever and penumbra aspiration systems. *World Neurology* 2011;7(6 Suppl):S16–23.
- Abou-Chebl A, Bajzer CT, Krieger DW, *et al.* Multimodal therapy for the treatment of severe ischemic stroke combining GPIIb/IIIa antagonists and angioplasty after failure of thrombolysis. *Stroke* 2005;36:2286–8.
- Saver JL, Goyal M, Bonafe A, *et al.* Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. *N Engl J Med* 2015;372:2285–95.
- Jovin TG, Chamorro A, Cobo E, *et al.* Thrombectomy within 8 hours after symptom onset in ischemic stroke. *N Engl J Med* 2015;372:2296–306.
- Goyal M, Demchuk AM, Menon BK, *et al.* Randomized assessment of rapid endovascular treatment of ischemic stroke. *N Engl J Med* 2015;372:1019–30.
- Berkhemer OA, Fransen PS, Beumer D, *et al.* A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med* 2015;372:11–20.
- Campbell BC, Mitchell PJ, Kleinig TJ, *et al.* Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Engl J Med* 2015;372:1009–18.
- Spiotta AM, Vargas J, Turner R, *et al.* The golden hour of stroke intervention: effect of thrombectomy procedural time in acute ischemic stroke on outcome. *J Neurointerv Surg* 2014;6:511–16.
- Turk AS, Frei D, Fiorella D, *et al.* ADAPT FAST study: a direct aspiration first pass technique for acute stroke thrombectomy. *J Neurointerv Surg* 2014;6:260–4.
- Turk AS, Spiotta A, Frei D, *et al.* Initial clinical experience with the ADAPT technique: a direct aspiration first pass technique for stroke thrombectomy. *J Neurointerv Surg* 2014;6:231–7.
- Turk AS, Nyberg EM, Chaudry MI, *et al.* Utilization of CT perfusion patient selection for mechanical thrombectomy irrespective of time: a comparison of functional outcomes and complications. *J Neurointerv Surg* 2013;5:518–22.
- Trouillas P, von Kummer R. Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. *Stroke* 2006;37:556–61.
- Hassan AE, Chaudhry SA, Miley JT, *et al.* Microcatheter to recanalization (procedure time) predicts outcomes in endovascular treatment in patients with acute ischemic stroke: when do we stop? *AJNR Am J Neuroradiol* 2013;34:354–9.
- Turk AS, Turner R, Spiotta A, *et al.* Comparison of endovascular treatment approaches for acute ischemic stroke: cost effectiveness, technical success, and clinical outcomes. *J Neurointerv Surg* 2015;7:666–70.